* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Anal Cancer and Human Papilloma Virus - Dana
Survey
Document related concepts
Clostridium difficile infection wikipedia , lookup
Trichinosis wikipedia , lookup
Dirofilaria immitis wikipedia , lookup
Sarcocystis wikipedia , lookup
Microbicides for sexually transmitted diseases wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
Schistosomiasis wikipedia , lookup
Hepatitis C wikipedia , lookup
Coccidioidomycosis wikipedia , lookup
Sexually transmitted infection wikipedia , lookup
Oesophagostomum wikipedia , lookup
Neonatal infection wikipedia , lookup
Hepatitis B wikipedia , lookup
Hospital-acquired infection wikipedia , lookup
Transcript
Anal Cancer in Women and the Human Papilloma Virus Kimberly Perez, MD Gastrointestinal Medical Oncology November 6, 2015 Disclosures • I have no relationships to disclose. • I will discuss the use vaccines in a manner not approved by the U.S. Food and Drug Administration. • But in accordance with ACIP recommendations. Epidemiology: Anal Cancer in Women • Represents 0.4% of all new cancer cases in the United States. • Incidence is 1.8 per 100,000 persons overall, with 2 per 100,000 in women. • Incidence has been rising 2.2%/year in men and women. • It is estimated that 4,630 women in 2015 will be diagnosed with anal cancer in the United States, and 610 will die of their disease. American Cancer Society, 2015 Human Papilloma Virus – HPV • Genome consists of a circular double-stranded DNA molecule of ~8000bp • HPV types differ by >10% in the LI gene sequence • 199 different HPV types have been fully sequenced, and nearly all cluster into three genera: α-HPV, β-HPV, and γ-HPV • α-HPV isolate from mucosal and genital lesions; β and γ isolate from skin Anal cancer and HPV • Distribution of HPV genotypes in the anus is more heterogeneous than in the cervix, and it has been demonstrated that a greater proportion are of low-risk HPV types • Most common non-oncogenic HPV-53 and -66 • Most common oncogenic HPV-51, -52 and -16 • Detection of anal HPV is associated with: – a higher lifetime number of anal and vaginal sex partners – younger age at first anal intercourse – history of Chlamydia and anogenital warts. Types by histologic/genomic subtypes Overall Distribution, Overall Prevalence of HPV among 2107 Young Adult Women from Costa Rica Castro et al. J Infect Dis. 2012; 206: 1103 Mechanism of HPV Infection • Progression of infection is similar to cervical cancer which occurs over 1 to 3 decades. • Persistent infection of the same HPV type leads to high-grade squamous intraepithelial anal lesions eventually resulting in anal cancer • Despite this similarity, cervical cancer is 4 times more common than anal cancer. This may be due to higher clearance rate in anal cancer. Clearance of HPV anal infections • 87% of anal HPV infections are cleared within the 1st year • Rate of clearance of HPV from those with HPV anal infection: 9.2 per 100 woman-months with a median duration of 150 days. – Slowest clearance were HPV-59 (350 days) and HPV-58 (252 days). – Median clearance for HPV-16 and -18 were 123 and 212 days respectively. Clin Infect Dis. 2009; 48(5): 536 Sequential cervical and anal HPV infection • Acquisition of anal HPV infection increases significantly among women with a cervical HPV co-infection with 1 or more additional HPV types • Risk of incidental cervical HPV infection increases significantly among women with an anal HPV infection of 1 or more additional HPV types compared to women without a preceding anal HPV infection. • Risk of acquisition of a new anal HPV infection increased 20-29% among women with an cervical co-infection with any HPV type Goodman et al. The Journal of Infectious Diseases 2011; 203: 335-340 Castro et al. J Infect Dis. 2012; 206; 1103 Cancer Risk based on HPV subtype • Relative Risk varied by phylogenetic species • α3/α15 and α1/α8/α10 types are associated with a greater likelihood of infecting the anus among women with a preceding same-type infection at the cervix. • Risk of cervical HPV infection following an anal HPV infection with a concordant genotype was 8.8 (95% CI: 6.4-12.2). α 9/α11 had a slightly higher probability than other HPV types Goodman et al. J Infect Dis 2011; 201(9): 1331 Co-infection correlation with cervical cancer Veo et al. Tumor Biol. 2015; 36: 5399 Prognostic implications • Single-institution, retrospective analysis • 50 patients; stage I-III anal squamous cell carcinoma treated with concurrent chemotherapy and radiation • 84% were HPV+ (90% HPV-16) • HPV+ had more advanced disease at diagnosis (stage IIIA 45.2%, stage IIIB 28.6%) compared to HPV- (stage IIIA 37.5%, stage IIIB 0%) Results: – 5yr DFS – HPV+ 92.5% vs HPV- 50% – 5yr OS – HPV+ 93.3% vs HPV- 66.7% Rivenda et al. ecancer. 2015; 9:529 - 9-valent HPV Vaccine - ADVAXIS immunotherapy– BrUOG study THERAPEUTIC IMPLICATIONS Will the 9-valent vaccine impact the incidence of anal cancer? Serrano et al. Eur J of Cancer. 2015; 51:1732 ADXS11-001 Lm-LLO Immunotherapy and Chemo/IMRT for Anal Cancer Kimberly Perez, Howard Safran, Kara-Lynne Leonard, Thomas Dipetrillo, Nicholas Oldenburg, Adam Klipfel, Steven Schecter, Matthew Vrees, Leslie Roth, Nishit Shah, Lakshmi Rajdev, Kayla Rosati Brown UniversityOncology Group Research Consortium ADXS11-001 • HPV DNA is present in the majority of anal cancer • ADXS11-0011 immunotherapy is a live attenuated Listeria monocytogenes (Lm) bioengineered to secrete an HPV-16 E7 protein fused with a truncated fragment of listeriolysin O (tLLO) • tLLO is a virulence factor of Lm. It enables the bacterium to escape from the phagolysosome. • Innate powerful immune response to Lm, especially to listeriolysin (tLLO). Unlike peptides or viruses, there is no immune tolerance or neutralizing antibodies • Biosafety level 1-2. No fecal, urine shedding or person-to-person transmission; vector cleared within 24 hours with antibiotics. ADXS11-001 Is Taken Up By Antigen Presenting Cells (APC) • After infusion of Lm-LLO immunotherapy, Lm are taken up by APC. • Since listeriolysin can break through the phagolysosome, the fusion protein tLLO-E7 is free in the cytoplasm of APC and activate MHC class I and class II immune responses • HPV transformed tumors now “seen” as pathogeninfected and targeted by T-Cells ADXS11-001 with mitomycin/5-FU/IMRT for Locally Advanced Anal Cancer: Brown University Study Open Label Phase 1/2 Study • • • • N = 25 Primary stage II-III anal cancer High risk of recurrence HPV-positive ADXS11-001 1x109 cfu x 4 (1 prior to chemoRT and 3 post, q 28 days) as a 500 ml infusion over 30 min Biopsy Diagnosis Biopsy 6 months 6 weeks IMRT Mito/5-FU ADXS11-001 #1 Day -10 to 14 • • 28 days 28 days Follow up Primary Efficacy Endpoint: 6-month CR-rate Mito/5-FU ADXS11-001 #2 Day +10 post IMRT ADXS11-001 #3 ADXS11-001 #4 Premeds with Naprosyn (500 mg BID, day -1 & 0) & Promethazine (25 mg BID, predose 8 hr) Ampicillin is given day 3-9 after each ADXS11-001 dose Patient Characteristics (N=11) Age, years <50 >50 but <75 Median Range No. 1 9 62 37-71 Male Female 5 6 II III 4 7 N0 6 N1 N2 N3 0 1 4 Sex Stage Lymph node involvement ADXS11-001 Related Toxicities Adverse Event Flu-like Symptoms Migraine Hypotension HypoK* Chills/rigors Nausea Back pain Fever Grade 2 Grade 3 Grade 4 1 1 1 3 2 1 2 1 2 1 *These AEs occurred during dosing time point but are also included with overall AEs. Acute Grade 3 toxicities related to ADXS11-001: − Chills/rigors (N=2) − Back pain (N=1) − All toxicities were within 24 hours of dosing Preliminary RFS Data On ADXS11-001 T4N3 11 T3N0 10 T3N0 9 T3N3 8 T2N0 7 T4N0 6 T3N3 5 T4N0 4 T2N2 3 T3N3 Patient progressed systemically Patient expired unrelated to study treatment 2 0 200 400 600 Relapse Free Survival (Days)* Note: Patient #1 enrolled but was never treated on study 800 1000 * as of Sep 27, 2015 Conclusion • It is common for anal and cervical HPV infections to occur consecutively • The high degree of genotype-specific concordance indicates a common source of infection. • HPV+ anal carcinoma may be associated with an improved prognosis. • Due to the significant correlation between anal cancer and HPV, immunotherapy will be playing a larger role in therapeutic protocols.